

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX - 0105

Inventors: Ali et al.

Serial No.: 09/700,700

Filing Date: November 20, 2000

Examiner: Unknown

Group Art Unit: 1645

Title: A Novel Method of Diagnosing,  
Monitoring, and Staging Prostate  
Cancer

I, Nathan P. Letts, Registration No. 36,581, certify that this correspondence is being depositing with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents and Trademarks, Washington, D.C. 20231.

On this date:

Nathan P. Letts Registration No. 36,581

03 AUG 23 2010 10:56

#  
9  
KN

12/05/01

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

- (XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the

date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

- ( ) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
- ( ) Certification in Accordance with §1.97(e) is set forth below; or
- ( ) The fee of \$180.00 as set forth in §1.17(p) is attached.
- ( ) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1).
- (XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.
- (XX) A copy of the of the PCT Search Report for WO 99/60162 which corresponds to the instant US application 09/700,700 is included.
- ( ) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449

(modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. \_\_\_\_\_, filed , for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

- (XX) Due to the large size of some references, only relevant portions have been submitted. The included portions are as follows: WO 00/55174 A1 (pp. 1-13, 25, 98-104, 129, 245-612, sequence listing pages 99-100). Full text of abbreviated reference is available if requested.
- (XX) All listed references are in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-0434. This form is submitted in duplicate.

Respectfully submitted,



Nathan P. Letts  
Registration No. 36,581

Date: 11/20/01

DiaDexus, Inc.  
343 Oyster Point Blvd.  
South San Francisco, CA 94080  
(650) 246-6400

RECEIVED  
U.S. PATENT AND TRADEMARK OFFICE  
03 AUG 28 AM 10:55

RECEIVED BY THE UNITED STATES  
PATENT AND TRADEMARK OFFICE

Documents: Information Disclosure Statement Transmitted  
Letter; USPTO Form-1449 including 6  
references, and PCT search report.

Serial No.: 09/700,700  
Title: A Novel Method of Diagnosing, Monitoring and  
Staging Prostate Cancer  
Applicant : Ali et al.  
Filed: November 20, 2000  
Docket No.: DEX-0105  
Date Sent: 11/20/2001

